PuraPharm (HKG:1498) agreed to issue HK$20 million of 6% convertible bonds maturing in two years to Protoss Global Opportunities Fund, according to a Thursday Hong Kong bourse filing.
The bonds are convertible into a maximum of a little over 40.8 million conversion shares at HK$0.49 apiece.
The shares represent around 7.08% of the traditional Chinese medicine company's enlarged issued share capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.